Novartis AG (ADR) news

   Watch this stock
Showing stories 11 - 20 of about 162   

Articles published

NVS 93.37 -0.83 (-0.88%)
price chart
Amgen, Inc. Fails To Block Novartis AG (ADR) From Launching Biosimilar
A federal appeals court on Wednesday rejected Amgen Inc.'s (NASDAQ:AMGN) request for a temporary injunction to block Novartis AG (ADR) (NYSE:NVS) from launching a biosimilar version of Amgen's blockbuster drug, Neupogen, in the US. According to ...
Novartis to begin selling Neupogen copy in US  MarketWatch
Novartis (NVS) Launches Zarxio: First Biosimilar in the U.S.  Nasdaq
Novartis AG (ADR) (NVS) Stock Update: Decline Driven By Forex Headwinds
Novartis AG (ADR) (NYSE:NVS) stock has registered a decline of 6.06% over the past three months, aided in large part by the global market chaos that's bogging down the entire healthcare sector's stock performance.
News Recap - Novartis (NVS), China Mobile (CHL), Facebook (FB), General ...  Techsonian (press release)
Novartis AG (ADR) (NVS) Looks At Performance Based Pricing System Ahead Of ...
Novartis AG (ADR) (NYSE:NVS) seems to have heard the feelings of a number of people, who were not happy with the higher costs spent towards new drugs.
Novartis AG (ADR) (NYSE:NVS) Adds Spinifex Pharmaceuticals to its Portfolio
Will Novartis AG (ADR) Buy Pfizer Inc. Biosimilar Remicade?
Pfizer Inc. (NYSE:PFE) nears the completion of its $16 billion acquisition of Hospira Inc. (NYSE:HSP). The deal, which was agreed upon by the two parties in February, secured approval from the European regulators earlier this week, and now awaits ...
Novartis AG Moves Closer To EU Market With Heart Drug
Novartis AG ADR (NYSE:NVS) received positive feedback for its drug; Entresto (sacubitril/valsartan), from the Committee for Medicinal Products for Human Use (CHMP).
Novartis AG (NVS) Stock Soars On Heart-Failure Drug Approval
The US Food and Drug Administration (FDA) has approved Novartis AG's (ADR) (NYSE:NVS) new heart-failure drug, Entresto, the agency announced in a press release on Tuesday.
Novartis' Heart Failure Drug Entresto Receives FDA Approval - Analyst Blog  Nasdaq
Novartis Heart Failure Drug Entresto Receives FDA Approval
How Biogen Inc Gained From Novartis AG (ADR) MS Drug Label Update
Novartis AG (ADR) (NYSE:NVS) recently suffered a potential blow to its revenue stream from its top-selling multiple sclerosis drug, Gilenya.
GlaxoSmithKline plc (ADR) (GSK), Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY ...
The stocks include London-based GlaxoSmithKline plc (ADR) (NYSE:GSK), Switzerland-based Novartis AG (ADR) (NYSE:NVS) and France-based Sanofi SA (ADR) (NYSE:SNY).
GlaxoSmithKline Plc (ADR) (NYSE:GSK) Unveils Big Business Growth Targets  WallStreetPR (blog)
GlaxoSmithKline scraps HIV spinout, reports higher Q1 profit  Proactive Investors USA & Canada
Novartis AG (ADR) (NYSE:NVS) Mereo BioPharma Group Ltd
Novartis AG (ADR) (NYSE:NVS) would continue to hold a stake in the success of the three compounds which it will spin-off to Mereo BioPharma for further development.
Novartis AG (ADR) Declines As Merck andamp; Co., Wins Patent Battle
Novartis AG ADR (NYSE:NVS) declined 2.3% during yesterday's trade as the company lost a patent battle to Merck & Co.